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A 15 year-old grey Thoroughbred gelding presented for investigation of chronic weight loss and recent onset of
respiratory difficulty. Clinical examination confirmed tachypnoea with increased respiratory effort. Thoracic
ultrasound examination detected pleural effusion. The dyspnoea was related to the large volume of pleural effusion
and, following post-mortem examination, to the presence of a large mediastinal mass. Multiple pigmented masses,
likely melanomas, were detected peri-anally. Thoracic radiography, cytological examination of the pleural fluid and a
fine needle aspirate of a thoracic mass led to a presumptive diagnosis of malignant melanoma and this was con-
firmed at post mortem examination. Further metastatic spread to the central nervous system and right guttural
pouch was also identified. In conclusion this case manifests the potential malignant behaviour of equine melano-
mas, and a review of proposed therapies for melanoma treatment highlights the therapeutic options and current
areas of research.
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Melanin is a pigment produced by melanocytes in the
basal layer of the epidermis. It is proposed that, in grey
horses, a disturbance in melanin metabolism and trans-
fer associated with progressive greying of the hair, due to
increasing age, results in intra-cellular accumulation of
pigment. Excess pigment deposition then stimulates for-
mation of new melanoblasts or increased melanoblast
activity resulting in focal areas of overproduction and
neoplastic transformation of melanocytes [1]. Melanocy-
tic neoplasms have been reported to represent up to
18.7% of all equine cutaneous neoplasms [2].
Although it has been stated that 66% of equine melano-
mas may become malignant [3], results of more recent
clinicopathological studies have varied. MacGillivray [4]
reported that 14% of dermal melanomas may become ma-
lignant, but stated that this figure was likely an overesti-
mate as benign melanomas are infrequently submitted. A* Correspondence: metcalfelucy@hotmail.com
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reproduction in any medium, provided the orlater study investigating a group of 296 Lipizzaners re-
ported a 50% incidence of melanomas and no clinical evi-
dence of malignancy [5].
The following report describes a case of malignant
melanoma with the discussion focussing on available
treatment modalities and therapeutic and preventative
measures currently being developed.Case history and clinical findings
A 15 year-old grey Thoroughbred gelding was referred
to the University College Dublin Veterinary Hospital
(UCDVH) for investigation of respiratory difficulty of
three weeks duration. The horse had a history of insidi-
ous weight loss over the past year and had recently de-
veloped depression, inappetance, pyrexia and pectoral
oedema. Pigmented peri-anal masses, likely melanomas,
had been noted since purchase three years ago. Recent
treatment by the referring veterinarian included a com-
bination of antibiotics, non-steroidal anti-inflammatories
and bronchodilators.
On presentation, the horse was quiet, alert and re-
sponsive with a body condition score of 3.5/9. Clinicall Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Lateral radiograph of the left mid-dorsal thorax.
A well-marginated soft tissue opacity is visible ventral to and superim-
posed on the thoracic vertebrae, extending from intercostal spaces 6-13.
Figure 2 Cytospin preparation of pleural fluid showing
pigmented vacuolated cells, likely melanophages (arrows).
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creased respiratory effort. Mucous membranes appeared
pink, slightly tacky and capillary refill time was 3 seconds.
Multiple pigmented masses, likely melanomas (approxi-
mately 1.5 cm diameter) were detected peri-anally. A
small, firm, well circumscribed mass was palpable in the
right parotid region. Upon auscultation, there were bilat-
erally increased lung sounds in the dorsal lung fields and
reduced vesicular sounds bilaterally in the ventral lung
fields. As the horse was exhibiting respiratory difficulty a
rebreathing examination was not performed. Based on the
clinical evidence of hypovolaemia, an intravenous catheter
was placed and treatment begun with intravenous fluids
(Compound sodium lactate, 2.5 ml/kg/hour IV). A main-
tenance rate was administered until further diagnostic
evaluation had been performed.
Initial investigation
Arterial blood gas analysis parameters were within refer-
ence ranges. Haematology revealed a mild neutrophilic
inflammatory response (white blood cell count 14.4 ×
109/L, reference range 4.4 – 9.0 × 109/L; neutrophil
count 12.8 × 109/L, reference range 2.2-5.8 × 109/L).
Serum biochemistry revealed total hyperbilirubinaemia
(194.2 umol/L, reference range 5-51 umol/L). Thoracic
ultrasonography revealed a large volume of hypoechoic
fluid present in the pleural cavity to the level of the
tuber ischii bilaterally.
The left side of the chest was drained, under ultra-
sound guidance, with a 24 Fr thoracic trochar at the
level of the elbow in the 8th intercostal space (ICS); 25 li-
tres of proteinaceous serosanguinous fluid was slowly
drained. Repeat thoracic ultrasonography revealed a soft
tissue structure extending from ICS 6-13 on the left side
of the thorax. The structure extended ventrally from the
dorsal extent of the thoracic cavity. Radiographic exam-
ination of the lung fields on the left side of the horse
confirmed the location of the soft tissue opacity. The
structure was superimposed over the mid-thoracic verte-
bral bodies and was therefore estimated to be 12 cm in
dorsoventral distance (Figure 1). Fine needle aspiration
of the mass was performed and the darkly pigmented
tissue obtained submitted for cytological examination
along with a sample of the pleural fluid.
Cytological analysis reported the pleural fluid to be a
modified transudate; large cells with abundant foamy
cytoplasm containing material consistent with pigment
(likely melanophages) were seen on cytospin examination
(Figure 2). The fine needle aspirate smears revealed mela-
nocytes with multiple cytological criteria of malignancy in-
cluding variable pigmentation, multinucleation, moderate-
to-marked anisocytosis and anisokaryosis, variable nu-
cleus:cytoplasmic ratio and nuclear moulding (Figure 3). A
presumptive diagnosis of malignant melanoma was madeand following consultation with the owner a decision was
made for euthanasia of the horse.
At post mortem examination large multifocal to co-
alescing black firm nodular masses were observed
expanding and distending the mediastinum and extend-
ing multifocally throughout the pleural lining of the
intercostal spaces and diaphragmatic surface. Similar
masses were present in the right guttural pouch adjacent
to the internal carotid artery and within the right sub-
mandibular salivary gland. A solitary black nodule was
noted on the dural surface of the spinal cord in the region
of T13 and within the meninges between the rostral
border of the cerebellum and the dorsal aspect of the mid-
brain. Histological sections of perianal skin, lung tissue,
pleura, brain, spinal cord and oesophagus revealed multi-
nodular, unencapsulated, infiltrative, densely cellular, ex-
pansile neoplasms composed of spindle to epithelioid cells
Figure 3 Fine needle aspirate smear. There are multiple
cytological criteria of malignancy: anisokaryosis (black arrow), nuclear
moulding (red arrow).
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marked pleomorphism and contained round to oval nu-
clei, single prominent basophilic nucleoli and eosinophilic
cytoplasm containing variable amounts of melanin. Mi-
totic figures ranged from 2 – 5 per high powered field.
Numerous tumour cell emboli were noted in lymphatics
within the interlobular septae of the lung. This confirmed
the diagnosis of malignant melanoma.
Discussion
The horse described in this report had multiple small
perianal masses consistent with the benign melanomas
reported in approximately 80% of aged grey horses [6].
Until clinical symptoms developed and subsequently
progressed there was no indication of the widespread
metastatic nature of this neoplasm.
Traditionally, equine melanomas were classified based
on their growth patterns into three groups: benign mela-
nomas which grow slowly for years without metastasis,
malignant transformation of a previously benign melan-
oma and malignant melanoma from the outset [2]. A
later comprehensive study suggested that there are 4
clinically different forms: melanocytic nevi, dermal mel-
anoma, dermal melanomatosis and anaplastic malignant
melanoma [6]. Melanocytic nevi occur in young horses
of all coat colours. They frequently occur singularly, in
atypical sites and are benign. Dermal melanomas are
generally single masses that occur in typical locations i.e.
ventral tail and perineum in grey horses and surgical ex-
cision is curative [6]. Dermal melanomatosis is differen-
tiated clinically, but is histologically indistinguishable
from dermal melanoma. Melanomatosis is characterised
by multiple lesions, often coalescing, in typical locations
occurring in grey horses older than 15 years of age. These
are not surgically curable and have a high metastatic rate
[2]. Anaplastic malignant melanoma is reported in agednon-grey horses, and although rare is the most aggressive
form, leading to widespread metastasis within one year of
diagnosis [6].
According to the classification system described by
Valentine the case described in the present report clinic-
ally represented dermal melanomatosis i.e. multiple peri-
anal lesions in an aged horse [6]. However the detection
of multifocal, infiltrative, expansile masses with emboli
present within lymphatics, in association with a chronic
lesion, suggested malignant transformation of a previ-
ously benign melanoma. These histological findings cor-
relate with the traditional classification system described
by Scott and Miller [2]. This discrepancy highlights a
limitation of the current classification systems and the au-
thors suggest that staging of equine melanomatous tu-
mours would result in better treatment and prognostic
advice being given to clients. Veterinary oncologists use the
human TNM staging system to denote clinical or patho-
logical stage of canine tumours. This system is based upon
physical examination findings, diagnostic imaging and
histopathology and could be adapted for use in equidae.
In contrast to reports indicating that cases of equine
melanoma rarely have clinical signs referable to metasta-
ses, despite a high metastatic rate being detected at nec-
ropsy [7], euthanasia of this horse was based upon
clinical symptoms secondary to melanoma metastases.
The severe respiratory signs resulted from a combination
of the mass effect of the large mediastinal melanoma
and the consequences of a large volume of pleural effu-
sion on lung function. The pleural fluid likely accumu-
lated due to a combination of malignant exudation and
the space-occupying effect of the mediastinal melanoma.
However despite the lungs being the most common in-
ternal organ system affected [8], thoracic melanoma is
rare and pleural effusion secondary to melanoma has
only once been reported to the authors’ knowledge [4].
There was no evidence of melanocytes on pleural fluid
cytology; highlighting the importance of additional test-
ing to determine the underlying cause in cases present-
ing with pleural effusion.
By the time a definitive diagnosis in this case had been
made, disease progression was too advanced to offer any
reasonable treatment options. However the external
melanomas were present for a number of years and earl-
ier therapeutic options might have been possible.
Review
Sharp surgical excision, CO2 laser excision and cryosurgery
are often curative in cases of small well-demarcated dermal
melanomas [6]. However in advanced cases the size and ex-
tensive invasion of local tissues may preclude complete
removal. More recent therapeutic approaches have com-
bined excision or surgical debulking with additional treat-
ment modalities including cisplatin [9]. Cisplatin is a
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Intra-lesional cisplatin emulsion (powdered cisplatin,
adrenaline and sesame oil) injected on 4 occasions, was re-
ported to control tumour growth locally in 81% of cases;
there was no effect on development of new tumours in
other areas [9]. Implantation of cisplatin-containing bio-
degradable beads, considered to reduce operator risk, re-
portedly resulted in resolution of the tumour for at least
2 years in all 12 grey horses for which follow-up was avail-
able [10]. Cisplatin is likely only suitable for treating mel-
anomas with a mass effect or early lesions prior to
metastasis. There are no reports of success in treatment of
the surrounding tissue with other therapeutic options i.
e.5-fluorouracil, BCG and cryotherapy.
Cimetidine, a histamine H2-receptor antagonist, has
been reported to have anti-neoplastic properties that may
improve survival in patients with melanoma. Its mecha-
nisms of action are multifactorial with histamine reported
to be a potential growth factor for melanoma cells, breast
and colon cancer cell lines [11]; involved in regulation of
angiogenesis and an inhibitor of the immune response.
Interestingly histamine levels have been shown to be
nearly 3 times greater in humans with solid malignant tu-
mours [12]. Cimetidine has also been shown to inhibit E-
selectin expression resulting in decreased tumour cell ex-
travasation [13]. Goetz [14] reported partial to complete
remission in 3 horses following administration of oral ci-
metidine (2.5 mg/kg bwt TID for 4-12 months). Other in-
vestigators have not documented this clinical effect,
possibly as the drug seems to be most effective in rapidly
developing tumours [15].
Tumour cells express antigens recognisable as non-self
by the immune system. These antigens are weakly im-
munogenic [16]. Current research is focusing on the devel-
opment of immunotherapeutic approaches: immunization
or immune stimulation [17,18]. Initial studies reported suc-
cessful treatment of equine melanoma using a laboratory-
prepared whole-cell autogenous vaccine [17] however this
non-specific immunostimulation is strongly discouraged by
other investigators [19]. Interestingly autologous subcuta-
neous implantation of freeze-thawed cubes of sarcoid tis-
sue has been reported successful in small groups of horses
[20]. To the authors’ knowledge this simple technique has
been trialled, without adverse effects, in a number of prac-
tices, as adjunctive treatment of melanoma, and is an area
warranting further controlled studies.
As the mechanisms of secondary immunosuppression
are investigated it should become possible to target spe-
cific immunological functions. Heinzerling et al. [21]
injected equine melanoma metastases with a plasmid,
encoding the immunostimulatory human interleukin-12,
inducing approximately 60% tumour reduction. More re-
cently a placebo-controlled study using equine IL-12
and IL-18 reported activation of the immune system andsignificant tumour regression [22]. Other investigators
[23] have developed an experimental protocol involving
cytokine-enhanced tumour vaccination plus suicide gene
therapy. This led to a significant reduction in size (50-
100%) and perceived improvement in quality of life.
In the United States there is a DNA plasmid vaccine, en-
coding human tyrosinase (HuTyr), licensed for the treat-
ment of canine melanoma. This xenogenic vaccine utilises
the 92% homology of human and canine tyrosinase to pro-
duce a tyrosinase-specific anti-tumour response. The
equine tyrosinase sequence has a 90% homology to the
human sequence therefore cross-reactivity of the HuTyr
DNA vaccine is an area warranting further research [24].
While the heritability of melanoma (0.36) implies a
strong genetic basis for prevalence, the mode of inherit-
ance is inconclusive [5]. Rieder et al. [25] investigated the
genetic mechanisms involved in retarding metastatic
events in affected grey horses. They hypothesised an evo-
lutionary advantage not present in solid-coloured horses,
which show accelerated tumour proliferation, and sug-
gested linkage of the ‘grey-gene’ and the ‘melanoma
susceptibility-gene’. This could direct selective breeding;
reported to be successful in reducing melanoma incidence
in pigs [26].
Conclusions
In conclusion, veterinarians should recognise that dermal
melanomas can indeed have life-threatening conse-
quences. As a profession we are responsible for improving
client awareness of the risk of malignant transformation of
these ‘benign’ cutaneous tumours.
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